OR WAIT 15 SECS
Full-service contract research organization, Pivotal, has announced its acquisition of Akcelis, a Belgian company that specializes in patient engagement, recruitment, and retention.
Full-service contract research organization, Pivotal, has announced its acquisition of Akcelis, a Belgian company that specializes in patient engagement, recruitment, and retention, in a March 3, 2020 press release.
“This acquisition fits perfectly with our commitment to bringing innovation to the clinical development process to deliver efficiencies for our clients,” said Lidia Farr, vice-president Corporate Development and Finance at Pivotal, in the press release. “Akcelis will bring advanced, proprietary and analytics-driven technology and services to customise the most efficient and cost-effective approach to significantly improve site selection and patient enrolment and retention strategies for our clients’ clinical trials. As we focus on delivering this value for our customers, we are pleased to welcome our new colleagues to Pivotal to become part of our solution-oriented culture and help advance drug development to improve patient lives.”
“Pivotal’s expertise in clinical research and Akcelis’ patient-centric approach to accelerate patient recruitment are the winning combination for scientifically elegant and patient-friendly clinical trials,” added Barbara D’haene and Nathalie Niclaus, Akcelis managing directors and founders, in the press release. “We look forward to positively impacting Pivotal’s clinical research excellence by implementing innovative digital patient recruitment strategies.”
Through this acquisition, Pivotal hopes to utilize Ackelis’ experience and analytics-driven services to recruit and retain unique patients in clinical trials that are considered to be hard-to-recruit. Additionally, the integration of Ackelis will afford Pivotal the opportunity to increase its services offering.